| NCT ID | NCT07478380 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul Medeniyet University |
| Condition | Pediatric Critical Illness |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-03-10 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Arterial blood gas analysis is commonly used in pediatric intensive care units (PICUs) to assess oxygen and carbon dioxide levels in critically ill children. However, arterial blood sampling is invasive, can be painful, and may need to be repeated frequently. Transcutaneous monitoring provides a noninvasive method to continuously measure oxygen (pO₂) and carbon dioxide (pCO₂) levels through the skin, but its accuracy in critically ill pediatric patients requires further evaluation. The purpose of this observational study is to compare transcutaneous pO₂ and pCO₂ measurements with arterial blood gas values in pediatric intensive care unit patients. By analyzing paired measurements obtained simultaneously during routine clinical care, this study aims to evaluate the agreement between transcutaneous and arterial measurements, with a particular focus on whether transcutaneous pO₂ can serve as a reliable alternative to arterial sampling. The results of this study may help clarify the role of transcutaneous monitoring in pediatric intensive care and may contribute to reducing the need for invasive blood sampling in selected patients.
Eligibility Criteria
Eligibility Criteria Inclusion Criteria: * Age between 1 month and 18 years * Admission to the Pediatric Intensive Care Unit (PICU) * Presence of an arterial catheter allowing arterial blood gas (ABG) sampling * Simultaneous or paired transcutaneous pCO₂ and pO₂ monitoring available * Hemodynamically stable at the time of measurement Exclusion Criteria: * Severe skin disease, burns, or local skin infection at the transcutaneous sensor site * Severe peripheral perfusion impairment (e.g., refractory shock or high-dose vasopressor support) * Congenital or acquired conditions interfering with accurate transcutaneous measurements * Technical failure or inability to obtain reliable transcutaneous readings * Missing or incomplete paired ABG-transcutaneous measurement data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07478380 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 18 Years, studying Pediatric Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07478380 currently recruiting?
Yes, NCT07478380 is actively recruiting participants. Contact the research team at drayseasik@gmail.com for enrollment information.
Where is the NCT07478380 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07478380 clinical trial?
NCT07478380 is sponsored by Istanbul Medeniyet University. The trial plans to enroll 50 participants.